Cohance Lifesciences Intrinsic Value
COHANCE Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹170.72 | ₹136.58 - ₹204.86 | -39.0% | EPS: ₹7.76, Sector P/E: 22x |
| Book Value Method | asset | ₹699.75 | ₹629.77 - ₹769.73 | +150.0% | Book Value/Share: ₹708.08, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹559.80 | ₹503.82 - ₹615.78 | +100.0% | Revenue/Share: ₹878.46, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹559.80 | ₹503.82 - ₹615.78 | +100.0% | EBITDA: ₹548.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹699.75 | ₹559.80 - ₹839.70 | +150.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹83.97 | ₹75.57 - ₹92.37 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹119.89 | ₹107.90 - ₹131.88 | -57.2% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹559.80 | ₹503.82 - ₹615.78 | +100.0% | ROE: 14.3%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹351.61 | ₹316.45 - ₹386.77 | +25.6% | EPS: ₹7.76, BVPS: ₹708.08 |
Want to compare with current market value? Check COHANCE share price latest .
Valuation Comparison Chart
COHANCE Intrinsic Value Analysis
What is the intrinsic value of COHANCE?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Cohance Lifesciences (COHANCE) is ₹559.80 (median value). With the current market price of ₹279.90, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹83.97 to ₹699.75, indicating ₹83.97 - ₹699.75.
Is COHANCE undervalued or overvalued?
Based on our multi-method analysis, Cohance Lifesciences (COHANCE) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.08 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 14.3% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 22.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.75x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Cohance Lifesciences
Additional stock information and data for COHANCE
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹288 Cr | ₹162 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹359 Cr | ₹178 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹457 Cr | ₹360 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹330 Cr | ₹262 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹383 Cr | ₹228 Cr | Positive Free Cash Flow | 8/10 |